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Abstract

Author Manuscript

Transcellular propagation of tau aggregates may underlie the progression of pathology in
Alzheimer’s disease (AD) and other tauopathies. Braak Staging (B1, B2, B3) is based on phosphotau accumulation within connected brain regions: entorhinal cortex (B1); hippocampus/limbic
system (B2); and frontal and parietal lobes (B3). We previously developed a specific and sensitive
assay that uses flow cytometry to quantify seeding activity based on fluorescence resonance
energy transfer (FRET) in cells that stably express tau reporter proteins. In a tauopathy mouse
model, we have detected seeding activity far in advance of histopathological changes. It remains
unknown whether individuals with AD also develop seeding activity prior to accumulation of
phospho-tau. We measured tau seeding activity across four brain regions (hippocampus, frontal
lobe, parietal lobe, and cerebellum) in 104 fresh-frozen human AD brain samples from all Braak
stages. We observed widespread seeding activity, notably in regions predicted to be free of
phospho-tau deposition, and in detergent-insoluble fractions that lacked tau detectable by ELISA.
Seeding activity correlated positively with Braak stage and negatively with MMSE. Our results are
consistent with early transcellular propagation of tau seeds that triggers subsequent development
of neuropathology. The FRET-based seeding assay may also complement standard
neuropathological classification of tauopathies.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized by learning and memory deficits and brain
deposition of extracellular amyloid beta plaques and intracellular neurofibrillary tangles. In
comparison to amyloid beta plaque load, tau accumulation better correlates with cognitive
disturbances [3, 18, 28, 35], suggesting a fundamental role in neurodegeneration. The
precise toxic form(s) of tau is unknown, but evidence suggests that transcellular propagation
of tau aggregates, or seeds, could underlie disease progression [12, 13, 16, 19, 25, 29, 37].
Indeed, we and others have found that tau has essential prion properties [11, 12, 31]. The
prion model predicts that tau seeds escape one neuron, are internalized by another, and serve
as a template to convert native tau monomer into an ordered assembly [8, 12, 15, 20, 24, 31].
In prior work, we have hypothesized that transcellular propagation of tau seeding activity
underlies the pattern of neuropathology in tauopathies such as AD [16, 32].

Author Manuscript

Tau pathology in AD develops progressively in synaptically connected brain regions. This
forms the basis of Braak Staging [6, 7, 30, 34, 40], a well-established method that scores
accumulation of phospho-tau based on AT8 antibody staining of specific brain regions [5].
While Braak staging has proved very useful, variance in staining and analysis adds a
subjective aspect to the diagnosis of AD and other tauopathies. Furthermore, these methods
are bounded by the detection limits of immunohistochemistry, while more sensitive methods
could highlight earlier or more widespread abnormalities.
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To quantify tau seeding activity we previously developed a cellular biosensor assay [21].
This is based on stable expression of tau repeat domain (RD) containing a single diseaseassociated mutation (P301S) that is fused to cyan or yellow fluorescent protein (CFP or
YFP). Exogenous tau aggregate seeds delivered to the cell interior with cationic lipids
(Lipofectamine) trigger aggregation of intracellular RD-CFP/YFP by acting as a
conformational template. The close approximation of CFP and YFP within an aggregate
results in fluorescence resonance energy transfer (FRET) that is quantified by flow
cytometry. This enables determination of tau aggregate seed “titer” over 3 orders of
magnitude. We have not observed cross-reactivity with other amyloid proteins in the seeding
assay [21, 31], and immunodepletion with an anti-tau antibody eliminates seeding activity
from samples [21, 38]. Thus the assay appears highly sensitive and specific.

Author Manuscript

We have previously determined that aged, healthy human brains and tau knockout mice lack
tau seeding activity [21]. By contrast, tau seeding activity progressively increases with age
in the PS19 tauopathy mouse model (which expresses 1N,4R tau containing the P301S
mutation), and anticipates neuropathological changes (AT8, MC1, and thioflavin staining)
by many months [21]. These results are consistent with the idea that tau seeding triggers
subsequent development of neuropathology. However, it is unknown whether a similar
process might occur in AD. To test this prediction, we have measured tau seeding activity in
fresh-frozen human brain specimens from multiple brain regions, across all Braak stages.
We correlated seeding activity with Braak stage, clinical parameters, and tau biochemistry.
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MATERIALS & METHODS
Cell culture
HEK 293T cells were grown in DMEM (Gibco) supplemented with 10% fetal bovine serum
(Sigma-Aldrich), 1% penicillin/streptomycin (Gibco), and 1% GlutaMax (Gibco). Cells
were cultured at 37 °C with 5% CO2 in a humidified incubator.
Brain Tissue

Author Manuscript

We analyzed fresh-frozen specimens from brains that were previously categorized by
qualified neuropathologists (C.L.W., N.J.C., P.T.N.). 40 subjects were staged according to
Braak criteria as B1, B2, or B3 (defined as Braak I-II, Braak III-IV, or Braak V-VI,
respectively). Subjects were diagnosed using standard tau histological measures (described
below) and the 2012 criteria specified by the National Institute on Aging and the
Alzheimer’s Association [5, 22]. Samples consisted of grey matter obtained from four
distinct brain regions (hippocampus, frontal lobe (Brodmann Areas 8/9), parietal lobe
(Brodmann Areas 39/40), or cerebellum) typically affected differentially with tau pathology
through AD progression. Negative control tissue was obtained from individuals with
psychiatric disturbance, or diagnosed with Huntington’s disease. In total, 126 brain
specimens were analyzed.
Sample preparation

Author Manuscript

Fresh-frozen brain tissues were suspended in TBS containing EDTA-free cOmplete protease
inhibitors (Roche) such that the total concentration was 10% w/vol. Samples were
homogenized at 75 watts with pulsing using a probe sonicator (Omni International) for 15
min on ice in a hood. Between each sample, we washed the probe with three isopropanol
and distilled water rinses to prevent cross-contamination. Lysates were centrifuged at 23,000
× g for 15 min, and the supernatant was retained (total fraction). Protein concentration was
measured with BCA (Pierce) and normalized between all samples at 2 µg/µl. Fractions were
aliquoted and stored at −80 °C until further use to avoid multiple freeze/thaw cycles.
Biochemical extraction
Biochemical extraction was performed as described previously [10]. Total fractions
(described above) were centrifuged at 100,000 × g for 60 min at 4 °C, and the supernatant
was collected (soluble fraction). Pellets were resuspended in 1% sarkosyl, incubated for 30
min at room temperature with shaking, and centrifuged again at 100,000 × g for 60 min at
4 °C. The resultant pellet was resuspended in TBS (insoluble fraction) [9]. Soluble and
insoluble tau fractions were standardized by volume for ELISA and seeding assays.
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Tau ELISA
A total tau “sandwich” ELISA was performed as described previously [1]. All antibodies
were kindly provided by Dr. Peter Davies (Albert Einstein College of Medicine). 96 well
round-bottom plates (Corning) were coated for 48 hours at 4 °C with DA-31 (aa 150–190)
diluted in sodium bicarbonate buffer (6 µg/mL). Plates were rinsed with PBS 3 times,
blocked for 2 hours at room temperature with Starting Block (Pierce), and rinsed with PBS 5
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additional times. Total (1 µL), soluble (1 µL), and insoluble (0.3 µL) fractions were diluted
in SuperBlock solution (Pierce; 20% SuperBlock, diluted in TBS), and 50 µL sample was
added per well. DA-9 (aa 102–150) was conjugated to HRP using the Lighting-Link HRP
Conjugation Kit (Innova Biosciences), diluted 1:50 in SuperBlock solution, and 50 µL was
added per well (15 µg/mL). Sample + detection antibody complexes were incubated
overnight at 4 °C. Plates were washed with PBS 9 times with a 15 sec incubation between
each wash, and 75 µL 1-Step Ultra TMB Substrate Solution (Pierce) was added. Plates were
developed for 30 min, and the reaction was quenched with 2M sulfuric acid. Absorbance
was measured at 450 nm using an Epoch plate reader (BioTek). Each plate contained a
standard curve, and all samples were run in triplicate.
Biochemical Quantification
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Tau concentration was calculated using GraphPad Prism software. Standard curves were
made using 2N,4R recombinant protein (rPeptide) ranging from 15.6 to 1000 pg/mL and
were fitted using the sigmoidal, 4PL, X=log(concentration) nonlinear regression model.
Samples were diluted so that concentrations fell on the linear portion of the standard curve.
Tau Seeding
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Tau seeding activity was quantified as detailed previously [17, 21]. HEK 293T cells stably
expressing the aggregation-prone repeat domain (RD) of tau containing the diseaseassociated P301S mutation tagged to either CFP or YFP were transduced with human brain
homogenates. At 60–65% confluency, transduction complexes consisting of lysate (either 20
µg total, 2 µl soluble, or 5 µl insoluble fraction), Opti-MEM (Gibco), and Lipofectamine
2000 (Invitrogen) were added to cells. Following treatment, cells were incubated for 24 hr
prior to harvesting for FRET flow cytometry. Prior to FRET flow cytometry, we always
confirmed visible RD-CFP/YFP inclusions in positive wells. Standardized seeding activity,
reported here, is a fold change over background level of biosensor cells treated with empty
liposomes, which is arbitrarily set at 1% positivity in the FRET gate.
FRET Flow Cytometry
FRET flow cytometry was performed as described previously [17, 21]. Following 24 hr
treatment, cells were trypsinized, centrifuged, and fixed in 2% paraformaldehyde (Electron
Microscopy Sciences). Cells were resuspended in flow cytometry buffer (HBSS, PBS, 1%
FBS, and 1 mM EDTA) and analyzed using the MACSQuant VYB flow cytometer (Miltenyi
Biotec). CFP, YFP, and FRET signals were detected with the following settings: CFP (405
laser; 450/50 filter), YFP (488 laser; 525/50 filter), FRET (405 laser; 525/50 filter). Samples
were run in quadruplicate, and 15,000–20,000 singlets were captured per well.

Author Manuscript

Flow Cytometry Analysis
FlowJo v10 software was used for analysis. Gating strategy was similar to that described
previously [17, 21]. CFP and YFP spillover into the FRET channel were excluded using
compensation and the “False FRET” gate. Empty liposome-treated cells were used as the
baseline for background seeding, and FRET-positive events were identified from a FRET vs.
CFP bivariate plot. The median fluorescence intensity (MFI) of FRET-positive events was
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recorded. Integrated FRET Density (IFD; the product of percent cells FRET-positive and
MFI) is presented here. This integrates the amount of seeding per population of cells with
the degree of seeding within a positive cell.
Confocal Microscopy
All cells were grown and treated on microslides. Cells were fixed with 4%
paraformaldehyde, and confocal images were obtained with a Zeiss LSM 780 Inverted
confocal/multiphoton microscope.
Heat Map

Author Manuscript

Heat maps were generated using MATLAB software (MathWorks). The Integrated FRET
Density values were log-transformed and colored on a red scale. Values less than 1.5-fold
above untreated controls (non-significant levels) are shaded with light blue. The remaining
values are shaded from light-to-dark blue on a continuum, with the latter representing the
highest fold increase in IFD. If no sample was available, the rectangle is filled with grey
dots.
Immunohistochemistry
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Paraffin sections were cut at 4 µm thickness on a rotary microtome, mounted on positively
charged glass slides, and air-dried overnight. Sections were deparaffinized in xylene and
alcohol, pretreated in 98% formic acid for 5 min at room temperature, and rinsed in water.
Immunostaining was performed at room temperature on a Bond III automated
immunostainer (Leica Biosystems Inc) using phospho-tau monoclonal antibody AT8 (Pierce
Biotechnology; 1:200 for 30 minutes) and the Bond Polymer Refine detection system, which
includes H2O2 block, EDTA-based epitope retrieval solution, rabbit anti-mouse IgG
secondary antibody, anti-rabbit poly-HRP-IgG, DAB, and hematoxylin counterstain.
Sections were dehydrated in a graded series of ethanol dilutions and xylene, mounted on
coverslips, and reviewed on a Ni-U light microscope (Nikon Instruments Inc.). For
preparation of photomicrographs, slides were imaged on an Aperio ScanScope CS whole
slide imager (Leica) using a 20X objective, and selected fields captured using Aperio
ImageScope v12 software.
Statistics
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For all seeding experiments, cells treated with empty liposomes served as the control group.
We used a two-tailed t-test and set significance at p <0.01. For correlational analyses, we
performed nonparametric Spearman rank-order tests. r values represent the correlation
between seeding in each brain region and age, MMSE, or Braak stage, with significance set
at p <0.05.

RESULTS
Tau seeding detected across brain regions and Braak stages
Braak staging requires detection of phospho-tau pathology in discrete brain regions. To test
for a relationship of Braak staging and tau seeding activity, we used the FRET flow
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cytometry assay to quantify seeding activity in homogenates prepared from fresh-frozen
brain specimens from all Braak stages, across four regions (hippocampus, frontal and
parietal lobes, and cerebellum). We analyzed tissue from 40 individuals previously staged as
B1, B2, or B3 based on standard histopathological criteria (Supplemental Fig.1) and 7
additional individuals not reported to harbor tau pathology. Where possible, we analyzed
multiple brain regions from the same subject.
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All negative samples lacked seeding activity in each brain region (Fig. 1a–d). B1 samples
consistently exhibited tau seeding activity in the hippocampus, but not in other regions (Fig.
1a–d). B2 samples all exhibited hippocampal tau seeding (Fig. 1a), and B3 samples
uniformly scored positive in hippocampus, frontal, and parietal lobes (Fig. 1b,c). In many
instances, we observed seeding activity in brain regions that usually lack tau pathology, as
monitored by histology. For example, more than half of B1 samples, in which tau pathology
is generally limited to entorhinal cortex, had seeding activity in the hippocampus (Fig. 1a)
and often in cortical regions (Fig. 1b,c). B2 samples, in which pathology is generally
restricted to limbic regions, frequently exhibited seeding activity in frontal and parietal lobes
(Fig. 1b,c). Finally, in B3 cases we even observed seeding in cerebellum, despite the fact that
this region does not typically exhibit tau pathology (Fig. 1d). To ensure that seeding activity
was specific to tau, we performed immunodepletion experiments on a subset of samples.
Following incubation with either a negative control antibody (IgG) or an anti-tau antibody
(AT8), we consistently observed a significant reduction in seeding activity when lysate was
immunodepleted with AT8, but not IgG (Fig. 1e). Cerebellar seeding activity was depleted
less efficiently. Possibilities for this are discussed below.
Seeding activity correlates with lower MMSE score and higher Braak stage
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We next tested for correlation of seeding activity with other clinical or pathologic
characteristics. Age did not correlate with seeding activity in any brain region (Fig. 2a–c).
Seeding activity and cognitive status (as measured by the Mini-Mental State Examination
(MMSE)) negatively correlated (Fig. 2d–f), particularly in the parietal lobe. Seeding activity
correlated highly with Braak stage (Fig. 2g–i) in frontal and parietal lobes.
Seeding activity by region within individual brains

Author Manuscript

Braak and Braak first reported progressive and stereotypical neurofibrillary tangle (NFT)
accumulation in AD brains over two decades ago [6, 7]. In recent years, numerous mouse
studies have demonstrated that tau aggregates inoculated into the brain trigger spreading tau
pathology [2, 12, 13, 23, 25, 27, 31, 36]. Further, we previously observed a steady increase
in tau seeding activity in the PS19 tauopathy mouse brain, even in the absence of seed
inoculation [21, 39]. However, it is unknown how seeding activity might vary across brain
regions at different Braak stages within individuals. Thus, we charted the previous seeding
data with a heat map, organized by individual. Tissue from four brain regions was not
always available for all subjects (denoted by solid white boxes), although for every
individual, at least two brain regions were provided. For nearly every brain in which seeding
was detectable, we observed the highest seeding in hippocampus, next highest in neocortex,
and lowest in cerebellum (Fig. 3). Additionally, most cases contained higher seeding activity
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in frontal rather than parietal lobes, consistent with the original pathological characterization
by Braak and Braak [6].
Seeding detects pathology more sensitively than biochemistry
Accumulation of detergent-insoluble tau is associated with progressive pathology. Thus, we
tested the relative sensitivity of solubility analysis of tau vs. its seeding activity. We
extracted total, soluble, and sarkosyl-insoluble fractions from each brain sample [9] and
measured tau levels using an ultra-sensitive ELISA developed by the Peter Davies laboratory
[1]. We detected tau in all total (Fig. 4a) and soluble (Fig. 4b) fractions, regardless of brain
region or Braak stage, whereas we observed a more variable presence of detergent-insoluble
tau (Fig. 4c), which correlated with the reported Braak stage: minimal in B1, moderate in
B2, and extensive in B3, excluding cerebellum, which lacked insoluble tau as measured by
ELISA.
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We then analyzed each biochemical fraction for seeding activity. We observed seeding in
many total (Fig. 4d), soluble (Fig. 4e), and insoluble (Fig. 4f) fractions with the exception of
negative control subjects, but no correlation with tau levels. Importantly, a large number of
B1, B2, or B3 samples had no apparent insoluble tau as characterized by ELISA, yet they
exhibited strong seeding activity (Fig. 4f, highlighted in yellow). Overall, we detected
seeding activity in 82 of 104 insoluble sample fractions. Of note, 18 of these 82 (~22%)
initially scored negative when seeding was first evaluated from the total fraction. This
indicates that when the total lysate scores negative it is still possible to enrich seeding
activity using detergent fractionation. In no instance did we detect seeding in the total
fraction but not the insoluble fraction. We conclude that tau seeding activity does not
correlate with total tau protein level, and that the FRET seeding assay is highly sensitive for
the detection of tau aggregate seeds.

DISCUSSION

Author Manuscript

Tau pathology in AD develops progressively in regions of brain with known synaptic
connectivity, and prion-like transcellular propagation of seeds has been proposed to explain
this observation [4, 11, 21, 31]. This model makes a strong prediction that seeding activity
should anticipate subsequent development of neuropathology. To test this idea, we quantified
tau seeding activity in fresh-frozen brain samples derived from 40 individuals at different
Braak stages, across four brain regions. We detected proteopathic tau seeding activity across
specimens more extensively than is typically observed by histopathology or biochemical
studies alone. In particular, we observed robust seeding activity in many hippocampal
samples from B1 brains and in many parietal and frontal lobe samples from B2 brains. In a
subset of B3 brains, we even observed seeding activity within the cerebellum, which
typically has no detectable tau pathology based on immunohistochemistry. Importantly,
despite trying several anti-tau antibodies in addition to AT8, together or in sequence, we
never achieved full depletion of cerebellar seeding activity. Despite the fact that we have
never observed cross-seeding events between other amyloids and tau, we conclude that some
seeding activity in the cerebellum might represent a non-tau factor, or tau species for which
the epitopes are masked or unavailable due to posttranslational modifications, protein
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interactions, or distinct strain structure. Taken together, however, our findings support the
model of transcellular propagation of tau pathology, and suggest that seed detection might
augment standard histopathological analysis.
Seed detection as a quantitative adjunct for neuropathology
Pathological assessment of NFTs was first described by Braak and Braak several decades
ago [6, 7], and their AT8 staining protocols are now the gold standard for pathological
characterization of AD. Although staining methods are well established and the progression
of phospho-tau pathology is predictable, the analysis of a brain still requires the subjective
impression of a qualified neuropathologist. While the recently revised grouping of Braak
stages described by the National Institute on Aging and the Alzheimer’s Association [22]
may help to standardize diagnosis, Braak staging by immunohistochemistry remains an
imperfect metric of tau pathology.
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The FRET flow cytometry assay we have previously described sensitively and specifically
quantifies tau seeding activity in biological samples [17, 21]. We have never observed nonspecific seeding of tau by heterologous fibrillar species, suggesting that it is both sensitive
and specific [21, 31]. The assay is user-friendly and relatively high-throughput, with a
continuous signal spectrum. It requires appropriate positive and negative controls, along
with a dedicated flow cytometer and an experienced operator, which may limit its broad
applicability.
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With this assay we detected tau seeding activity in human lysates across multiple brain
regions and Braak stages. Seeding activity correlates with Braak staging, but appears to be
more sensitive to the presence of pathological tau. This suggests that the seeding assay could
complement standard histopathology. Quantification of seeding activity in multiple regions
or sub-regions of brain might reveal new aspects of tauopathy that cannot be visualized by
immunohistochemistry or biochemistry, especially early in disease.
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The tau seeding assay requires relatively small amounts of brain tissue (<100 µg), which
may be beneficial when samples are limited. In this study, we used fresh-frozen tissue,
which precluded simultaneous analysis of the same brain region by histopathology.
However, future work will determine the feasibility of using fixed tissue, which we expect
will be compatible given the resistance of amyloid beta and alpha synuclein seeds to
formaldehyde fixation [14, 33]. If compatible with the tau seeding assay, fixed tissue
analysis could open up important possibilities for combining it with neuropathological
analysis in the same region. While evaluation of seeding activity in one small sample may
not accurately represent the entire brain structure, its relatively high throughput nature
enables multiple samples to be tested across brain regions without much additional labor. In
combination with current AT8 staining protocols, we anticipate that the two metrics together
might augment the detection, quantification, and characterization of tau pathology.
Seeding as an early marker of pathology
We observed that seeding activity generally correlates with the characteristic phospho-tau
staining patterns described by Braak staging. However, numerous tissue samples exhibited
obvious seeding activity prior to when Braak staging would predict tau pathology. For
Acta Neuropathol. Author manuscript; available in PMC 2018 March 02.
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example, according to B1 staging guidelines, phospho-tau is restricted to entorhinal cortex,
yet we observed seeding activity in >50% of B1 hippocampal homogenates. Similarly, in B2
brains, where tau pathology is limited to the entorhinal or limbic systems, we consistently
measured tau seeding activity in parietal and frontal lobes. In B3 brains we observed seeding
activity in every hippocampal and cortical sample tested, and even in occasional cerebellar
samples, which typically lack phospho-tau histopathology. Immunodepletion studies along
with previously-published material [31] suggest that the seeding activity quantified here is
tau-specific and not the result of cross-seeding from another pathological source. In addition
to standard histological patterns of tau pathology, seeding activity also proved to be more
sensitive than standard biochemical analysis of tau in brain lysates. In numerous cases
samples had no detectable insoluble tau based on an ultra-sensitive ELISA (detection level
of ~24 pg/mL tau [1]), but scored positive with the FRET flow cytometry assay. Thus, we
anticipate that the seeding assay might also augment standard biochemical analyses of
insoluble (i.e. pathological) tau.
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We previously observed that seeding activity is the earliest marker of disease in the PS19
tauopathy mouse model, as it appears months before multiple immunohistochemical markers
score positive, including AT8, PG5, and MC1 [21]. Because the current work did not
evaluate human tissue specimens in parallel for histopathology and seeding, as was done in
the mouse study, we cannot conclude with certainty that seeding activity precedes deposition
of phospho-tau in these human brain specimens. This must await simultaneous comparison
with both methods of very closely spaced sub-regions of brain. Seeding activity that is
detected prior to histopathological abnormality could be due to the presence of very small
tau assemblies that are seed-competent (trimer or above [26]), but that may not feature
abundant phosphorylation. Alternatively, the seeding species may be below the threshold of
detection of any type of immunohistochemistry. Regardless, we hope future work will be
able to determine the significance of seeding activity observed in the absence of
histopathological tau abnormalities.
Tau seeding and the prion hypothesis
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There is no evidence of inadvertent transmission of tau pathology between individuals.
Nonetheless, in experimental systems, we and others have observed that tau acts as a prion
in many other respects [11, 12, 31]. It is impossible to know whether trans-cellular
propagation underlies progression of disease in patients until we have an effective therapy
designed to block this process. However, the hypothesis that proteopathic seeds cause
pathology clearly predicts that seeding activity should develop prior to the occurrence of
neuropathology that is visible by stains for macromolecular protein assemblies. While this
study has a critical limitation in that the fresh-frozen tissues studied with the FRET assay are
not the same as those that were used for Braak staging of brains, the early and widespread
detection of seeding is consistent with the prion model to explain progressive accumulation
of tau pathology and neurological dysfunction in AD. We hope that future studies that
employ a similar multimodal assessment of human tissues will clarify these initial
observations.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Tau seeding activity is present in multiple brain regions and increases with Braak stage
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20 µg of clarified human brain lysate was transduced into Tau-RD-P301S CFP/YFP
biosensor cells, which were harvested for FRET flow cytometry after 24 hr. Hippocampus
(a), Frontal Lobe (b), and Parietal Lobe (c) all consistently scored positive for seeding from
B3 brains (represented by red squares). B2 brains (represented by blue triangles) also
demonstrated strong hippocampal seeding activity and moderate cortical seeding. B1
subjects (represented by green circles) consistently showed hippocampal seeding activity.
Cerebellum (d) contained seeding activity in a few B3 samples. Error bars denote SEM, and
dashed lines represent threshold for significant seeding (p <0.01), as compared to cells
treated with empty liposomes. Standardized seeding activity represents the fold change in
signal over negative control biosensor cells.
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Figure 2. Correlation of tau seeding with MMSE and Braak stage

We evaluated seeding activity with subject age (a–c), MMSE (d–f) and Braak stage (g–i)
using nonparametric Spearman correlational analyses. Age and seeding activity did not
correlate; MMSE and seeding activity negatively correlated; and Braak stage and seeding
activity positively correlated (p <0.05).
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Figure 3. Seeding activity determined by region in individuals
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Relative tau seeding activity was assessed in brain regions within the same individuals. Each
row represents an individual subject (n=47), and each column represents a specific brain
region. Samples not provided for a region are colored with grey dots. Representative seeding
values are shaded light to dark blue with the latter corresponding to highest seeding activity.
Seeding activity is highest in hippocampus and increases with Braak stage.
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Figure 4. Biochemical characterization of brain homogenates

Brain lysates were biochemically extracted, and subsequent fractions were quantified using
ELISA (a–c) and FRET flow cytometry (d–f). All samples contained total (a) and soluble (b)
tau. Insoluble tau (c) was measurable in only a subset of samples. Seeding activity was
present variably in all total (d) or soluble (e) fractions, and was present in almost all
insoluble fractions (f), even those that did not score positive with ELISA. The yellow box (f)
highlights 41 samples that were ELISA-negative and seed-positive.
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